Abstract:Immunoglobulin A vasculitis (IgAV; formerly Henoch Schonlein Purpura) is the most common form of childhood vasculitis. It can occur in any age and peaks around 4–6 years old. It demonstrates seasonal variation implicating a role for environmental triggers and geographical variation. The diagnosis is made clinically and 95% of patients will present with a rash, together with any from a triad of other systems—gastrointestinal, musculoskeletal, and renal. Most cases of IgAV in children have an excellent outcome. Treatment may be required during the acute phase for gastrointestinal involvement and renal involvement, termed IgAV nephritis (previously HSP nephritis), is the most serious long-term manifestation accounting for ~1–2% of all childhood end stage kidney disease (ESKD). It therefore requires a period of renal monitoring conducted for 6–12 months. Patients presenting with nephrotic and/or nephritic syndrome or whom develop significant persistent proteinuria should undergo a renal biopsy to evaluate the extent of renal inflammation and there are now international consensus guidelines that outline the indications for when to do this. At present there is no evidence to support the use of medications at the outset in all patients to prevent subsequent renal inflammation. Consensus management guidelines suggest using oral corticosteroids for milder disease, oral, or intravenous corticosteroids plus azathioprine or mycophenolate mofetil or intravenous cyclophosphamide for moderate disease and intravenous corticosteroids with cyclophosphamide for severe disease. Angiotensin system inhibitors act as adjunctive treatment for persisting proteinuria and frequently relapsing disease may necessitate the use of immunosuppressant agents. Renal outcomes in this disease have remained static over time and progress may be hindered due to many reasons, including the lack of reliable disease biomarkers and an absence of core outcome measures allowing for accurate comparison between studies. This review article summarizes the current evidence supporting the management of this condition highlighting recent findings and areas of unmet need. In order to improve the long term outcomes in this condition international research collaboration is urgently required.

[Research advances in the etiology and pathogenesis of immunoglobulin A vasculitis]

Pathogenesis of IgA Vasculitis: An Up-To-Date Review

IgA Vasculitis:A Review on Diagnosis and Management

IgA Vasculitis Update: Epidemiology, Pathogenesis, and Biomarkers

Progress in Pathogenesis of Immunoglobin A Nephropathy

Pathogenesis and treatment progress of antineutrophil cytoplasmic antibody-associated vasculitis

Serum Syndecan-1 Levels in Patients with Immunoglobulin A Vasculitis in Children

IgA vasculitis after COVID-19: a case-based review

Insight into the Interplay of Gd-IgA1, HMGB1, RAGE and PCDH1 in IgA Vasculitis (IgAV)

Genome-wide studies define new genetic mechanisms of IgA vasculitis

IgA vasculitis with nephritis: an overview of the pathogenesis and clinical characteristic

Clinical and Pathological Features of Patients with Antineutrophil Cytoplasmic Antibody‐associated Vasculitides Concomitant with IgG4‐related Disease

IgA vasculitis

SARS-CoV-2 as a trigger of IgA vasculitis: a clinical case and literature review

A Review of the Pathogenesis of IgA Vasculitis Nephritis in Children

The Clinicopathologic Characteristics and Complement Activation of Antineutrophil Cytoplasmic Antibody-associated Vasculitides with Glomerular IgA Deposition

Higher Serum Angiotensinogen is an Indicator of IgA Vasculitis with Nephritis Revealed by Comparative Proteomes Analysis

Pathophysiology and clinical manifestations of immune complex vasculitides

Childhood IgA Vasculitis (Henoch Schonlein Purpura)—Advances and Knowledge Gaps

Clinicopathological Features of Antineutrophil Cytoplasmic Antibodies Associated Vasculitis with Glomerular IgA Deposits

Navigating Adult-Onset IgA Vasculitis-Associated Nephritis